AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-26. Numbers and descriptions here follow the published literature rather than marketing material.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
(C4H2NH)n + 0.2 X → [(C4H2NH)nX0.2] The polymerization and p-doping can also be effected electrochemically. The resulting conductive polymer are peeled off of the anode. Cyclic voltammetry and chronocoulometry methods can be used for electrochemical synthesis of polypyrrole. Most recent micro and nano droplet researches have been conducted in the synthesis of polypyrrole microstructures using various fluid templates formed on different solid surfaces.
== Destaining == Proteins which were separated by 1D or 2D PAGE are usually visualised by staining with dyes like Coomassie brilliant blue (CBB) or silver. Although the sensitivity of the method is significantly lower, the use of Coomassie is more common for samples destined for mass spectrometry since the silver staining impairs the analysis. After excision of the protein band of interest from the gel most protocols require a destaining of the proteins before proceeding. The destaining solution for CBB contains usually the buffer salt ammonium bicarbonate (NH4HCO3) and a fraction of 30%-50% organic solvent (mostly acetonitrile). The hydrophobic interactions between protein and CBB are reduced by the organic fraction of the solution. At the same time, the ionic part of the solution diminishes the electrostatic bonds between the dye and the positively charged amino acids of the protein. In contrast to a mixture of water with organic solvent the effectivity of destaining is increased. An increase of temperature promotes the destaining process. To a certain degree (< 10%) the destaining procedure is accompanied with a loss of protein. Furthermore, the removal of CBB does not affect the yield of peptides in the mass spectrometric measurement. In the case of silver stained protein bands the destaining is accomplished by oxidation of the metallic silver attached to the protein by potassium ferricyanide or hydrogen peroxide (H2O2). The released silver ions are complexed subsequently by sodium thiosulfate.
Following the terrorist attacks of September 11, Bush issued an executive order that authorized the President's Surveillance Program. The new directive allowed the National Security Agency to monitor communications between suspected terrorists outside the U.S. and parties within the U.S. without obtaining a warrant, which previously had been required by the Foreign Intelligence Surveillance Act. As of 2009, the other provisions of the program remained highly classified. Once the Department of Justice Office of Legal Counsel questioned its original legal opinion that FISA did not apply in a time of war, the program was subsequently re-authorized by the President on the basis that the warrant requirements of FISA were implicitly superseded by the subsequent passage of the Authorization for Use of Military Force Against Terrorists. The program proved to be controversial; critics of the administration and organizations such as the American Bar Association argued that it was illegal. In August 2006, a U.S. district court judge ruled that the NSA electronic surveillance program was unconstitutional, but on July 6, 2007, the ruling was vacated by the United States Court of Appeals for the Sixth Circuit on the grounds that the plaintiffs lacked standing. On January 17, 2007, Attorney General Alberto Gonzales informed U.S. Senate leaders that the program would not be reauthorized by the President, but would be subjected to judicial oversight.
Sources: en.wikipedia.org
== See also == 1973 European Cup final – contested by the same teams 1996 UEFA Cup Winners' Cup final 1996 UEFA Cup final 1995–96 AFC Ajax season 1995–96 Juventus FC season AFC Ajax in international football Juventus FC in international football
And for a whole large class, there is no other road, especially for a nation so eminently practical and so contemptuous of theory as the Americans. The great thing is to get the working class to move as a class.” The Program of the Fourth Congress states, "We agitate to politically shake up the proletariat. The aim of our agitation is to draw the maximum number of workers into the political struggle. Communist propaganda is scientific, theoretical, political education. Our propaganda exposes capitalist production relations as the root cause of the social destruction rampant today. The class struggle is a political struggle; our propaganda convinces the workers that society cannot be organized to meet their basic demands without their seizing political power.” The Political Report to the Fourth Congress also sharply criticized the politics of the Communist Party (USA) focusing on the CP's advocacy of left-center unity. "For the CPUSA the most important goal is ‘unity of the working class in the battle against the corporations.’ By disregarding that imperialism objectively has split the working class—a phenomenon which Lenin identified over 75 years ago—the CPUSA proclaims the lofty goal of uniting the working class.
=== Additional instar === Two populations of C. brunneus have females that have an additional instar inserted between instar II and III termed instar IIa. Morphological characteristics of instar IIa are a mixture of instars II and III. Females are of an intermediate size and length between instars II and III. Wing buds closely resemble the wing buds of instar II but have more venation than the typical wing buds of instar II. Genitalia development is closer to the development of instar III development. Additional instars have been found in other acridid species that display sexual dimorphism in which females are larger than males such as C. parallelus. C. brunneus females on average are 3 to 4 times larger than males. The occurrence of the additional instar most likely reflects the habitat the C. brunneus females occur. Females with the additional instar have only been found to occur in the region of East Anglia in Britain. The longer summers in East Anglia may facilitate earlier hatching and an increased growth rate permitting the inclusion of instar IIa allowing the females to reach a larger size. Decreased availability of food may encourage rapid development also explaining the inclusion of an additional instar.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.